^
Association details:
| Biomarker: | CD20 underexpression |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Lunsumio (mosunetuzumab-axgb) (CD20 inhibitor, CD3 agonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.
Published date:
05/26/2022
Excerpt:
In pts with R/R B-NHL treated with M, low BL CD20 expression is associated with lack of response to M. During M tx, loss of tumor cell expression of CD20 is one mechanism of acquired resistance...
DOI:
10.1200/JCO.2022.40.16_suppl.7526
Trial ID:
